References
- Giles F, O'Brien S, Cortes J, et al Outcome of patients with acute myelogenous leukemia after second salvage therapy. Cancer. 2005;104:547–554.
- Grigoleit GU, Kapp M, Tan SM, et al Clofarabine based salvage chemotherapy for relapsed or refractory acute leukemias prior to allogeneic stem cell transplantation: results from a case series. Leuk Lymphoma. 2009;50:2071–2074.
- Bonate PL, Arthaud L, Cantrell WR, et al Discovery and development of clofarabine: a nucleoside analogue for treating cancer. Nat Rev Drug Discov. 2006;5:855–863.
- Jeha S, Gaynon PS, Razzouk BI, et al Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol. 2006;24:1917–1923.
- Faderl S, Gandhi V, O'Brien S, et al Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood. 2005;105:940–947.
- Karp J, Ricklis RM, Balakrishnan K, et al A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias. Blood. 2007;110:1762–1769.
- Faderl S, Ferrajoli A, Wierda W, et al Clofarabine combinations as acute myeloid leukemia salvage therapy. Cancer. 2008;113:2090–2096.